Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients  Florian Kronenberg, Arno Lingenhel, Ulrich Neyer, Karl Lhotta, Paul König, Martin Auinger, Martin Wiesholzer, Helene Andersson, Hans Dieplinger  Kidney International  Volume 63, Pages S113-S116 (May 2003) DOI: 10.1046/j.1523-1755.63.s84.23.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Prevalence of dyslipidemic factors in hemodialysis (HD) and CAPD patients. The definition of dyslipidemic factors is based on recent recommendations of the Medical Expert Group4. (A) The prevalence of elevated total and LDL cholesterol, triglycerides, and Lp(a) levels and decreased HDL cholesterol levels for HD and CAPD patients. (B) The frequency of concomitant dyslipidemic risk factors in each patient for HD and CAPD patients. For the sum of these risk factors we considered LDL, HDL cholesterol, triglycerides, and Lp(a). The frequency of concomitant dyslipidemic risk factors was significantly different between the two treatment groups (χ2 = 37.0, df = 4, P < 0.001). Kidney International 2003 63, S113-S116DOI: (10.1046/j.1523-1755.63.s84.23.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Frequency distribution (%) of apolipoprotein A-IV (apoA-IV) plasma concentrations in patients with end-stage renal disease treated by hemodialysis (HD) (N = 534) or continuous ambulatory peritoneal dialysis (CAPD) (N = 168) and 256 healthy controls. Pearson's χ2 test: HD vs. controls, P < 0.001; HD vs. CAPD, P = NS, CAPD vs. controls, P < 0.001. Kidney International 2003 63, S113-S116DOI: (10.1046/j.1523-1755.63.s84.23.x) Copyright © 2003 International Society of Nephrology Terms and Conditions